Cargando…

Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires

Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported anchor motif of the corresponding HLA-DR molecules was determined in 1994 based on a small number of peptide ligands and binding as...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholz, Erika Margaret, Marcilla, Miguel, Daura, Xavier, Arribas-Layton, David, James, Eddie A., Alvarez, Iñaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566978/
https://www.ncbi.nlm.nih.gov/pubmed/28871256
http://dx.doi.org/10.3389/fimmu.2017.00984
_version_ 1783258633164816384
author Scholz, Erika Margaret
Marcilla, Miguel
Daura, Xavier
Arribas-Layton, David
James, Eddie A.
Alvarez, Iñaki
author_facet Scholz, Erika Margaret
Marcilla, Miguel
Daura, Xavier
Arribas-Layton, David
James, Eddie A.
Alvarez, Iñaki
author_sort Scholz, Erika Margaret
collection PubMed
description Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported anchor motif of the corresponding HLA-DR molecules was determined in 1994 based on a small number of peptide ligands and binding assays. DR2a could display a set of peptides complementary to that presented by DR2b or, alternatively, a similar peptide repertoire but recognized in a different manner by T cells. It is known that DR2a and DR2b share some peptide ligands, although the degree of similarity of their associated peptidomes remains unclear. In addition, the contribution of each molecule to the global peptide repertoire presented by the HLA-DR15 haplotype has not been evaluated. We used mass spectrometry to analyze the peptide pools bound to DR2a and DR2b, identifying 169 and 555 unique peptide ligands of DR2a and DR2b, respectively. The analysis of these sets of peptides allowed the refinement of the corresponding binding motifs revealing novel anchor residues that had been overlooked in previous analyses. Moreover, the number of shared ligands between both molecules was low, indicating that DR2a and DR2b present complementary peptide repertoires to T cells. Finally, our analysis suggests that, quantitatively, both molecules contribute to the peptide repertoire presented by cells expressing the HLA-DR15 haplotype.
format Online
Article
Text
id pubmed-5566978
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55669782017-09-04 Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires Scholz, Erika Margaret Marcilla, Miguel Daura, Xavier Arribas-Layton, David James, Eddie A. Alvarez, Iñaki Front Immunol Immunology Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported anchor motif of the corresponding HLA-DR molecules was determined in 1994 based on a small number of peptide ligands and binding assays. DR2a could display a set of peptides complementary to that presented by DR2b or, alternatively, a similar peptide repertoire but recognized in a different manner by T cells. It is known that DR2a and DR2b share some peptide ligands, although the degree of similarity of their associated peptidomes remains unclear. In addition, the contribution of each molecule to the global peptide repertoire presented by the HLA-DR15 haplotype has not been evaluated. We used mass spectrometry to analyze the peptide pools bound to DR2a and DR2b, identifying 169 and 555 unique peptide ligands of DR2a and DR2b, respectively. The analysis of these sets of peptides allowed the refinement of the corresponding binding motifs revealing novel anchor residues that had been overlooked in previous analyses. Moreover, the number of shared ligands between both molecules was low, indicating that DR2a and DR2b present complementary peptide repertoires to T cells. Finally, our analysis suggests that, quantitatively, both molecules contribute to the peptide repertoire presented by cells expressing the HLA-DR15 haplotype. Frontiers Media S.A. 2017-08-21 /pmc/articles/PMC5566978/ /pubmed/28871256 http://dx.doi.org/10.3389/fimmu.2017.00984 Text en Copyright © 2017 Scholz, Marcilla, Daura, Arribas-Layton, James and Alvarez. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Scholz, Erika Margaret
Marcilla, Miguel
Daura, Xavier
Arribas-Layton, David
James, Eddie A.
Alvarez, Iñaki
Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
title Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
title_full Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
title_fullStr Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
title_full_unstemmed Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
title_short Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
title_sort human leukocyte antigen (hla)-drb1*15:01 and hla-drb5*01:01 present complementary peptide repertoires
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566978/
https://www.ncbi.nlm.nih.gov/pubmed/28871256
http://dx.doi.org/10.3389/fimmu.2017.00984
work_keys_str_mv AT scholzerikamargaret humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires
AT marcillamiguel humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires
AT dauraxavier humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires
AT arribaslaytondavid humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires
AT jameseddiea humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires
AT alvarezinaki humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires